Merck & Co. Inc., of Whitehouse Station, N.J., said the first patient was enrolled in its phase III ONCEMRK trial, designed to assess a once-daily investigational formulation of integrase inhibitor Isentress (raltegravir) as part of combination HIV therapy in treatment-naïve HIV-1-infected adults.